In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compugen Ltd.

https://www.cgen.com/

Latest From Compugen Ltd.

Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer

The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.

Deals Cancer

Israeli Biopharma Leaders Focus On Near-Term Targets

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.

Market Intelligence Innovation

BioBytes: Four Big Pharma Companies Cultivating AI-Based Start-ups

Through an Israeli innovation lab, four big pharma companies are fostering AI-driven start-ups to help solve industry problems.

Innovation Artificial Intelligence

Trials In Focus: Patient Advocacy Group Takes Trial Diversity To Capitol Hill

The Foundation for Sarcoidosis Research briefed US Congress on participation by Black patients in sarcoidosis and other rare disease trials. Also, the US FDA issued a draft guidance on psychedelic drug trials; Insilico is taking its AI-discovered IPF drug into Phase II; and Compugen and Jasper dosed patients in their oncology trials.

Clinical Trials Diversity & Inclusion
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Evogene, Compugen USA, Inc, Neviah Genomics Ltd
UsernamePublicRestriction

Register